Treatment of HER2-positive early breast cancer: How to best balance efficacy and toxicity?
Breast J
.
2018 Jul;24(4):459-461.
doi: 10.1111/tbj.12932.
Authors
Hamdy A Azim
1
,
Shaimaa Lasheen
1
,
Loay Kassem
1
Affiliation
1
The Department of Clinical Oncology, School of Medicine, Cairo University, Cairo, Egypt.
PMID:
29998620
DOI:
10.1111/tbj.12932
No abstract available
Publication types
Editorial
Comment
MeSH terms
Breast Neoplasms*
Carboplatin
Colony-Stimulating Factors
Docetaxel
Humans
Neoadjuvant Therapy
Receptor, ErbB-2
Trastuzumab*
Substances
Colony-Stimulating Factors
Docetaxel
Carboplatin
Receptor, ErbB-2
Trastuzumab